贝伐珠单抗联合卡铂紫杉醇一线治疗晚期黏膜黑色素瘤的随机II期研究
该随机开放标签II期研究纳入114例既往未治疗的晚期黏膜黑色素瘤患者,按2:1随机接受卡铂+紫杉醇联合或不联合贝伐珠单抗治疗。
要点
- 贝伐珠单抗联合卡铂紫杉醇显著延长晚期黏膜黑色素瘤患者的PFS和OS。
核心结论
- 在晚期黏膜黑色素瘤患者中,卡铂紫杉醇联合贝伐珠单抗较单用化疗显著改善PFS和OS。
研究设计与样本
- 随机、开放标签、II期研究,纳入114例既往未治疗的晚期黏膜黑色素瘤患者,按2:1随机分配。
- 联合组(CPB)接受卡铂(AUC 5)+紫杉醇(175 mg/m2)每4周一次+贝伐珠单抗(5 mg/kg)每2周一次;对照组(CP)仅接受卡铂+紫杉醇。
主要发现
- 未观察到新的安全性信号。
关键数值与推荐
- 主要终点为PFS,次要终点包括OS、客观缓解率和不良事件。
- 卡铂剂量按AUC 5计算,紫杉醇175 mg/m2,贝伐珠单抗5 mg/kg。
临床怎么用
- 对于既往未治疗的晚期黏膜黑色素瘤患者,可考虑在卡铂+紫杉醇基础上联合贝伐珠单抗以改善PFS和OS。
- 该方案的安全性未发现新信号,但需进一步III期研究确认获益。
局限性
- 为II期研究,样本量有限,结论需III期研究验证。
- 开放标签设计可能引入偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination with carboplatin plus paclitaxel (CPB) in patients with previously untreated advanced MM. PATIENTS AND METHODS: Patients were randomly assigned in a 2:1 ratio to receive carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m2) once every 4 weeks in combination with (CPB arm, 5 mg/kg) or without (CP arm) bevacizumab once every 2 weeks. Progression-free survival (PFS) was the primary end point. Secondary end points included overall survival (OS), objective response rate, and adverse events. RESULTS: We recruited 114 patients to our study. The median PFS was significantly longer in the CPB arm (4.8 months; 95% CI, 3.6 to 6.0 months) than in the CP arm (3.0 months; 95% CI, 1.7 to 4.3 months) (hazard ratio, 0.461; 95% CI, 0.306 to 0.695; P < .001). Objective response rates were 19.7% and 13.2%, respectively (P = .384). The median OS was also significantly longer in the CPB arm than in the CP arm (13.6 v 9.0 months; hazard ratio, 0.611; 95% CI, 0.407 to 0.917; P = .017). No new safety signals were observed. CONCLUSION: PFS and OS were significantly better in patients with metastatic MM who received bevacizumab in addition to CPB than in those who received CPB alone. A phase III study should be performed to confirm these benefits (ClinicalTrials.gov identifier: NCT02023710).
引用
- Yan X, Sheng X, Chi Z, et al. Randomized Phase II Study of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma. J Clin Oncol. 2021. PMID: 33444116. doi:10.1200/JCO.20.00902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。